Join Chadi as he engages with Petros Grivas, MD, PhD, Professor in the Clinical Research division of Fred Hutchinson Cancer Center, to unravel the groundbreaking updates in bladder cancer revealed at the ESMO Congress. Dr. Grivas provides a comprehensive overview, dissecting the advancements in the realms of muscle invasive bladder cancer, non-muscle invasive bladder cancer, and advanced bladder cancer. Delve into the specifics of EV-302, THOR, and many other studies and gain a deeper understanding of the implications these findings may hold for the future of bladder cancer treatment.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
